Quick Answer
Montelukast (Singulair) is a leukotriene receptor antagonist (LTRA) that blocks the action of cysteinyl leukotrienes — inflammatory lipid mediators that cause airway inflammation, mucus production, and nasal congestion in allergy and asthma. It is FDA-approved for allergic rhinitis and asthma but carries a 2020 black box warning for neuropsychiatric effects.
How Montelukast Works
Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are inflammatory lipid mediators produced by mast cells, basophils, and eosinophils during the late-phase allergic response. They are particularly potent bronchoconstrictors, nasal congestion promoters, and airway mucus stimulants — explaining why histamine-blocking antihistamines alone are insufficient for many patients with significant nasal congestion or asthma.
Montelukast selectively and competitively blocks cysteinyl leukotriene type 1 (CysLT1) receptors in the airways and nasal mucosa. By blocking leukotriene action, it reduces airway smooth muscle constriction, mucosal inflammation, and nasal congestion. Because it targets a different pathway than antihistamines, it provides complementary benefit when used in combination with H1 antihistamines.
FDA-Approved Uses and Comparative Efficacy
Montelukast is FDA-approved for seasonal allergic rhinitis (adults and children 2+), perennial allergic rhinitis (adults and children 6+), and mild-to-moderate persistent asthma (adults and children 12 months+). For allergic rhinitis, clinical guidelines place it as a third-line option behind nasal corticosteroids (first-line) and antihistamines (second-line) due to somewhat less robust nasal symptom control compared with nasal steroids.
Montelukast's relative advantage over antihistamines is that it addresses congestion better (through leukotriene pathway) while antihistamines better address sneezing and rhinorrhea (through histamine pathway). For patients whose predominant uncontrolled symptom is nasal congestion despite antihistamine use, adding or substituting montelukast may provide incremental benefit.
The 2020 Black Box Warning for Neuropsychiatric Effects
In 2020, the FDA added a black box warning to montelukast for serious neuropsychiatric effects, including agitation, aggression, anxiousness, dream abnormalities, hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (suicidality), tremor, and somnambulism (sleepwalking). These effects have occurred in patients with no previous psychiatric history.
The FDA guidance states that montelukast should generally be reserved for patients who have inadequate response or intolerance to preferred alternative therapy for allergic rhinitis. For allergic rhinitis, nasal corticosteroids and antihistamines have comparable or superior efficacy to montelukast without the neuropsychiatric risk. The risk-benefit analysis for rhinitis generally does not favor montelukast as first or second-line treatment.
Key Takeaways
- Montelukast blocks cysteinyl leukotriene receptors — reducing airway constriction, mucus, and nasal congestion.
- FDA-approved for allergic rhinitis and asthma — but third-line for rhinitis per clinical guidelines.
- 2020 FDA black box warning: neuropsychiatric effects including depression, suicidal thinking, and behavioral changes.
- Nasal steroids and antihistamines are preferred first- and second-line for allergic rhinitis over montelukast.
- Montelukast's role is most appropriate for patients with both rhinitis and asthma who may benefit from both conditions being addressed.
Related Guide
Allergy Treatment Hub →